Phase 2 Study of Azixa (MPC-6827) for the Treatment of Patients With Recurrent Glioblastoma Multiforme
The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Azixa
Phase: Phase 2
Ages Eligible For Study:
- Have histologically proven malignant Glioblastoma Multiforme in first or second relapse - Have failed prior Fractionated External Beam Cranial Irradiation or IMRT - Be at least 18 years old and with a life expectancy ? 8 weeks or ? 4 weeks if failed prior Avastin therapy - Have a Karnofsky performance status of ? 60 - Have adequate bone marrow function, liver function, and renal function before starting therapy